openPR Logo
Press release

With the Growing Demand for Blood Derived Products, Photopheresis Product Market is Expected to Gain Significant Traction During the Forecast Period

05-03-2017 03:25 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

With the Growing Demand for Blood Derived Products,

The global market for photopheresis products features an exceedingly consolidated competitive landscape, with the top three players accounting for over 95% of the market in 2015, observes Transparency Market Research in a recent report. These three companies, namely Mallinckrodt, Macopharma, and Med Tech solutions GmbH, stay competitive by investing in the development of new kits/devices capable of overcoming issues in existing products. Development of smaller, lighter, and faster devices tops the list of priority of these companies.

Browse Complete Report Details at: http://www.transparencymarketresearch.com/photopheresis-products-market.html

Companies are also attempting to educate and train healthcare practitioners and the masses with the view of spreading awareness about ECP therapy and its benefits. A recent instance of this is Mallinckrodt’s Therakos Institute. The company is educating patients, nurses, and technicians through clinical education and training related to the photopheresis operating modules and their benefits.

North America to Continue to Gain Massive Portion of the Pie

Transparency Market Research (TMR) states that the market will exhibit a 5.9% CAGR from 2016 through 2024. As a result, the market will rise to US$371.1 mn by 2024 from US$223.1 mn in 2015. In terms of product type, the segment of closed system photopheresis products accounted for over 80% of the overall market in 2015 and is expected to remain the dominant segment over the forecast period as well. North America, with over 52% of the global photopheresis products market in 2015, will continue to command a prominent position in the global market over the forecast period as well.

Government Reimbursements to Act as Strong Driving Force

Safer and effective treatment by using photopheresis technique is expected to be one of the potential drivers of the photopheresis products market during the forecast period. Most of the methods currently used for treating conditions such as graft-versus-host and cutaneous T-cell lymphoma lead to certain side effects. The promise of better safety and efficacy of the extracorporeal photopheresis (ECP) therapy has led to the rising preference of healthcare practitioners to this technique over other drug treatments.

Government bodies are also increasingly encouraging patients to undergo ECP therapy to treat a variety of diseases in the form of reimbursements for the therapy. The favorable reimbursement policies and the resultant coverage of medical expenses under government-supported refunds is encouraging patients to undergo ECP therapy to treat various disease conditions.

Furthermore, there has been a significant rise in the global population with cutaneous T-cell lymphoma (CTL), a rare type of non-Hodgkin lymphoma that affects the skin. According to the Cutaneous Lymphoma Foundation, the rate of incidence of CTL is nearly 1500 new cases per year in the U.S. and prevalence of continues to rise in the country as well as across the globe. Although several types of therapies are used to treat CTL, ECP is being increasingly considered the first line of therapy for treating CTL.

High Costs and Lengthy Treatments to Limit Adoption

Despite being reimbursed by the government in several regions across the globe, the cost of ECP therapy is significantly high. Moreover, the therapy takes longer time to perform and treat than many other popular treatments. It is estimated that on an average, the ECP therapy requires nearly two to three hours at a stretch for the treatment to complete for various disease. Also, the patient is required to undergo the treatment once every two weeks for a year. The cost of per treatment is around US$8000 per treatment.

Get the Premium Research Report of Photopheresis Products Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14771

On a whole, the time and money invested to complete the treatment is immense. This factor may make the treatment less attractive for many patients and may compel healthcare practitioners to switch to other low-cost and less time consuming treatments, restraining the overall growth prospects of the global photopheresis products market. The lack of enough ECP therapy centers across many developed and developing countries is also a key challenge for the market.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release With the Growing Demand for Blood Derived Products, Photopheresis Product Market is Expected to Gain Significant Traction During the Forecast Period here

News-ID: 522704 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for ECP

11 Chemistry Start-ups from the Netherlands will attend the ECP Summer Summit
- Brightlands Innovation Factory is an ECP Partner and Gold Sponsor - Event location: Henkel KGaA in Düsseldorf - Partnering has started: Several hundred Speed Dating appointments anticipated 11 September 2018, Frankfurt am Main The first ECP Summer Summit / European Chemistry Partnering will take place on September 25, 2018 in Düsseldorf at the headquarters of the consumer and industrial goods company Henkel. The Brightlands Innovation Factory from the Netherlands will introduce eleven Start-up
Minister Andreas Pinkwart is the Patron of the ECP Summer Summit
Prof. Dr. Andreas Pinkwart, Minister for Economic Affairs, Innovation, Digitization and Energy of the State of North Rhine-Westphalia, has assumed patronage of the first ECP Summer Summit. The summer version of the European Chemistry Partnering will take place on September 25, 2018 at the consumer and industrial goods company Henkel in its capacity as the main sponsor of the event. “The chemical industry is a pillar of prosperity and employment. This
Assisted Living Software Market By Key Vendors: AL Advantage, ALIS, iCareManager …
Qyresearchreports include new market research report Assisted Living Software to its huge collection of research reports. Several regional and global trends account for the attractive stride the global Assisted Living Software market is experiencing over the forecast period. The report offers a granular assessment of all such trends impacting the current outlook and emerging growth dynamics. The study on the global Assisted Living Software market highlights the key factors shaping the
MyBinding.com Partners with Akiles to Offer the CoilMac ECP Series Coil Binding …
HILLSBORO, OR, April 15, 2012 – MyBinding.com, one of the country's leading Internet retailers of binding machines and supplies, recently added the Akiles CoilMac ECP series binding equipment to their website. MyBinding.com has a long history of working with Akiles. Currently they offer a huge selection of Akiles binding machines, laminators, corner rounders, supplies, and more. The decision to add the CoilMac ECP series to their extensive Akiles inventory was
Virgin Media chooses Pixelmetrix Electronic Couch Potato™ (ECP) to monitor its …
Pixelmetrix, the global expert in Preventive Monitoring for digital television and IPTV networks, has signed an agreement with Virgin Media to roll out the Pixelmetrix Electronic Couch Potato™ (ECP) across its digital TV network. The ECP is a programmable test robot that monitors true customer viewing experience by providing measurements from the end point of the content delivery chain.  The Automated Channel Package Auditing feature of the ECP proved effective for quality assurance and monitoring of
Pixelmetrix Electronic Couch Potato™ (ECP™) - Now Shipping
IBC 2008, Amsterdam, September 12, 2008 – Pixelmetrix, the global expert in Preventive Monitoring for digital television and IPTV networks, is now shipping its Electronic Couch Potato™ (ECP™). Demonstrations are available at Pixelmetrix Booth 1C39. The Pixelmetrix Electronic Couch Potato™ (ECP™) is an after the network probe that measures and reports the end-users’ experience for delivered video services. Collecting telemetry from multiple ECPs™ distributed across a wide network and